Key result
APS/TMA phenotypes show no independent link to mortality in cancer hospitalizations after severity adjustment.
Why the study?
It was unclear whether excess mortality in cancer hospitalizations with APS and TMA phenotypes reflects an independent risk factor or complication-mediated risk.
Is the APS/TMA phenotype independently associated with increased in-hospital mortality among adult cancer hospitalizations?
Cross-Sectional (n=4,810,000)
Yes
Is the APS/TMA phenotype independently associated with increased in-hospital mortality among adult cancer hospitalizations?
APS/TMA phenotypes in cancer hospitalizations function as a failure-to-rescue signal mediated by complications and illness severity rather than an independent driver of mortality.
Answers are grounded in this paper and cite their sources.
APS/TMA phenotypes do not independently increase mortality in cancer hospitalizations; hypothesis-generating for complication-mediated failure-to-rescue in future studies.
11041 Background: Failure-to-rescue (FTR), defined as mortality following major inpatient complications, reflects both patient disease pathology and hospital rescue capacity. Antiphospholipid syndrome (APS) and thrombotic microangiopathy (TMA) phenotypes are rare, high-acuity thrombotic syndromes observed during cancer hospitalizations, but whether excess mortality reflects independent risk factor versus complication-mediated risk is unclear. Methods: A serial cross-sectional, hospitalization-level analysis was performed using the 2018–2022 Healthcare Cost and Utilization Project National Inpatient Sample (NIS). Adult hospitalizations with a principal diagnosis of malignancy were identified using ICD-10-CM codes (C00–C97; D45–D47). APS and TMA phenotypes were defined using any-diagnosis ICD-10-CM proxies for APS and TMA, including TTP/HUS, and combined as an APS/TMA phenotype. Because laboratory and medication data are unavailable in the NIS, exposures were analyzed as inpatient phenotypes rather than presumed diagnoses. Major complications included mechanical ventilation and acute kidney injury requiring dialysis. Failure-to-rescue was defined as in-hospital mortality among admissions with ≥1 major complication. National estimates incorporated discharge weights, hospital clustering, and stratification; multivariable models adjusted for All Patient Refined Diagnosis Related Group (APR-DRG) severity. Results: Among an estimated 4.81 million principal malignancy hospitalizations nationally, APS/TMA phenotypes occurred in 0.48% of admissions. Compared with non-phenotype admissions, APS/TMA phenotype hospitalizations had higher mortality (9.43% vs 4.35%) and higher rates of major complications, including mechanical ventilation (5.85% vs 2.57%) and dialysis-requiring acute kidney injury (2.11% vs 0.61%). In severity-adjusted modeling incorporating APR-DRG severity, APS/TMA phenotype was not independently associated with mortality (adjusted OR 0.99, 95% CI 0.70–1.40), indicating that excess mortality was largely mediated by complications and underlying illness severity. Conclusions: APS/TMA phenotypes identify a rare but high-acuity subgroup of cancer hospitalizations characterized by disproportionate ICU-level support and dialysis utilization, functioning as a national failure-to-rescue signal rather than an independent driver of mortality after severity adjustment. These findings highlight the importance of early recognition and severity-directed rescue strategies for high-risk thrombotic phenotypes during cancer admissions.
No takes yet. Share an insight, caveat, or question.
Tabbah et al. (2026) conducted a cross-sectional in Malignancy (n=4,810,000). APS/TMA phenotype vs. Non-phenotype admissions was evaluated on Mortality (severity-adjusted) (adjusted OR 0.99, 95% CI 0.70-1.40). APS/TMA phenotypes during cancer hospitalizations were not independently associated with mortality after severity adjustment.
Synapse has enriched 10 related papers. Consider them for comparative context: